BioSpace News Archive

OKYO Pharma Limited (NASDAQ: OKYO) announces that it will be rescheduling a Key Opinion Leader (KOL) event entitled “KOL Event Presenting Comprehensive Detailed Results from the Phase 2 Trial of OK-101 in Dry Eye Disease” originally planned for April 9th, 2024 at 12:00 PM ET until May 2024.

Adcentrx Therapeutics (“Adcentrx”), a biotechnology company revolutionizing Antibody-Drug Conjugate (ADC) therapeutics for cancer and other life-threatening diseases, announced today the appointment of Meng Jiang as Chief Financial Officer (CFO).

Research published in Lancet Infectious Diseases and supported by PolyBio Research Foundation provides the strongest evidence yet that the COVID virus can persist for months or years after infection.

9 April 2024, Abbisko Therapeutics Co., Ltd. announced the completion of patient enrollment for its pivotal Phase III trial, MANEUVER STUDY, for evaluating the efficacy and safety of pimicotinib in patients with tenosynovial giant cell tumor.

Transcenta Holding Limited and Agilent Technologies, announce a collaboration to develop a Claudin18.2 companion diagnostic to support TranStar301 global Phase III pivotal trial of Osemitamab in combination with Nivolumab and chemotherapy as first-line treatment in patients with CLDN18.2 expressing locally advanced or metastatic gastric or gastroesophageal adenocarcinoma.